South Korea Cancer Supportive Care Market
South Korea Cancer Supportive Care Market Summary
As per Market Research Future analysis, the South Korea cancer supportive-care market size was estimated at 522.75 USD Million in 2024. The South Korea cancer supportive-care market is projected to grow from 535.82 USD Million in 2025 to 686.05 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 2% during the forecast period 2025 - 2035
Key Market Trends & Highlights
The South Korea cancer supportive-care market is experiencing a transformative shift towards integrated and patient-centered approaches.
- The integration of technology in supportive care is enhancing patient engagement and treatment outcomes.
- There is a growing emphasis on psychological support services to address the mental health needs of cancer patients.
- Government initiatives and funding are increasingly supporting the development of comprehensive cancer care programs.
- The rising cancer incidence and advancements in treatment modalities are driving demand for innovative supportive care solutions.
Market Size & Forecast
| 2024 Market Size | 522.75 (USD Million) |
| 2035 Market Size | 686.05 (USD Million) |
| CAGR (2025 - 2035) | 2.5% |
Major Players
Roche (CH), Bristol-Myers Squibb (US), Amgen (US), Merck & Co (US), Novartis (CH), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB)
South Korea Cancer Supportive Care Market Trends
The cancer supportive-care market in South Korea is experiencing notable growth, driven by an increasing awareness of the importance of holistic treatment approaches for cancer patients. This market encompasses a range of services and products designed to alleviate the physical and emotional burdens associated with cancer treatment. As the population ages and the incidence of cancer rises, there is a growing demand for supportive care services that address not only the medical needs but also the psychological and social aspects of patient care. Furthermore, advancements in technology and the integration of telehealth services are enhancing accessibility to supportive care, allowing patients to receive necessary assistance from the comfort of their homes. In addition, the South Korean government is actively promoting initiatives aimed at improving the quality of life for cancer patients. This includes funding for research and development in supportive care therapies, as well as public health campaigns to educate patients and families about available resources. The emphasis on personalized care and patient-centered approaches is likely to shape the future of the cancer supportive-care market, as stakeholders seek to provide tailored solutions that meet the unique needs of individuals undergoing cancer treatment. Overall, the landscape appears promising, with various factors contributing to the expansion of this vital sector.
Integration of Technology in Supportive Care
The incorporation of digital health solutions is transforming the cancer supportive-care market. Telehealth platforms and mobile applications are facilitating remote consultations and monitoring, enabling patients to access support services conveniently. This trend is particularly relevant in South Korea, where technology adoption is high, allowing for enhanced communication between healthcare providers and patients.
Focus on Psychological Support
There is a growing recognition of the importance of mental health in cancer care. Supportive services that address psychological well-being, such as counseling and support groups, are becoming increasingly prevalent. This trend reflects a shift towards a more holistic approach to cancer treatment, acknowledging that emotional support is crucial for patient recovery.
Government Initiatives and Funding
The South Korean government is actively investing in programs aimed at improving cancer care. Initiatives include funding for research in supportive therapies and public health campaigns to raise awareness about available resources. Such efforts are likely to enhance the overall quality of care and support for cancer patients, fostering a more robust supportive-care market.
South Korea Cancer Supportive Care Market Drivers
Rising Cancer Incidence
The increasing incidence of cancer in South Korea is a primary driver for the cancer supportive-care market. According to the Korea Central Cancer Registry, cancer cases have been on the rise, with an estimated 250,000 new cases reported annually. This surge necessitates enhanced supportive care services to address the complex needs of patients. As the population ages and lifestyle factors contribute to higher cancer rates, the demand for supportive care services, including pain management and nutritional support, is expected to grow. The cancer supportive-care market is likely to expand as healthcare providers seek to improve patient outcomes and quality of life, indicating a robust market potential.
Government Policy and Regulation
Government policies and regulations play a crucial role in shaping the cancer supportive-care market. Recent initiatives aimed at improving cancer care infrastructure and funding for supportive services are likely to enhance access to care. The South Korean government has been increasing its investment in healthcare, with a focus on comprehensive cancer care. This includes support for programs that provide psychological counseling and nutritional assistance to cancer patients. As these policies evolve, they may create a more favorable environment for the growth of the cancer supportive-care market, ensuring that patients receive the necessary support throughout their treatment journey.
Increased Awareness and Education
There is a growing awareness of the importance of supportive care among patients, families, and healthcare professionals in South Korea. Educational initiatives aimed at informing stakeholders about the benefits of supportive care are gaining traction. This heightened awareness is likely to drive demand for services that enhance patient well-being during and after cancer treatment. As more individuals recognize the value of psychological support, pain management, and palliative care, the cancer supportive-care market is expected to expand. This trend indicates a shift towards a more holistic approach to cancer care, where supportive services are integrated into the overall treatment plan.
Growing Demand for Home-Based Care
The trend towards home-based care is becoming increasingly prominent in the cancer supportive-care market. Many patients prefer receiving care in the comfort of their homes, which can lead to improved satisfaction and quality of life. This shift is driven by advancements in telehealth and remote monitoring technologies, allowing healthcare providers to offer effective support without requiring patients to visit healthcare facilities. As the population ages and the preference for home care rises, the cancer supportive-care market is likely to see a significant increase in demand for home-based services. This trend suggests a transformation in how supportive care is delivered, emphasizing convenience and patient-centered approaches.
Advancements in Treatment Modalities
Innovations in cancer treatment modalities, such as immunotherapy and targeted therapies, are significantly impacting the cancer supportive-care market. As these treatments become more prevalent, patients often experience unique side effects that require specialized supportive care. For instance, the introduction of CAR-T cell therapy has shown promising results but also necessitates comprehensive management of adverse effects. The cancer supportive-care market must adapt to these advancements by providing tailored services that address the specific needs arising from new treatment regimens. This evolution in treatment approaches suggests a growing market for supportive care services that can effectively manage the complexities associated with modern cancer therapies.
Market Segment Insights
By Type: ESA (Largest) vs. G-CSFs (Fastest-Growing)
In the South Korea cancer supportive-care market, the distribution of market share among various segment values shows ESA as the dominant player, significantly outpacing G-CSFs, which have recently gained traction. Antiemetics, Bisphosphonates, Opioids, and NSAIDs also contribute to the market, but their shares remain comparatively smaller. Others, while important, do not play a major role in market dynamics. The presence of established products under ESA is driving its commanding presence. Growth trends in this segment indicate a rising demand for G-CSFs, propelled by an increase in chemotherapy treatments and the necessity to manage side effects like neutropenia. Simultaneously, the established stability of ESA remains a crucial factor, as healthcare providers increasingly opt for reliable solutions in supportive care. This landscape suggests a balanced growth trajectory, where newer entrants augment overall market performance.
ESA (Dominant) vs. Opioids (Emerging)
ESA has established itself as a dominant player within the South Korea cancer supportive-care market, primarily due to its efficacy in treating anemia associated with cancer treatments. As healthcare professionals prioritize patient management strategies, ESA's role in improving hemoglobin levels becomes increasingly critical. On the other hand, Opioids, while considered an emerging segment, face a nuanced position characterized by the growing demand for effective pain management in oncology patients. The increasing recognition of opioid efficacy, alongside advancements in pain management protocols, presents opportunities for Opioids to assert their position alongside ESA. The contrasting characteristics of these segments highlight ESA's strong foothold versus Opioids' potential for future growth.
By Application: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing)
In the South Korea cancer supportive-care market, the application segment is dominated by breast cancer treatments, which hold the largest share among other applications. This segment benefits from a well-established patient population and strong healthcare policies that promote early detection and comprehensive care. Following closely, lung cancer applications are gaining traction, driven by increasing awareness and advancements in treatment options. Growth trends indicate a significant rise in demand for supportive care in lung cancer, emerging as the fastest-growing segment. Factors such as an aging population and a rising number of cancer diagnoses contribute to this trend. Furthermore, innovations in treatment protocols and supportive therapies tailored to lung cancer patients are enhancing patient outcomes and propelling market expansion.
Breast Cancer: Dominant vs. Lung Cancer: Emerging
Breast cancer treatments represent a dominant force in the South Korea cancer supportive-care market due to their established protocols and high levels of patient engagement. This segment is characterized by a variety of treatment options, including chemotherapy and targeted therapies, which are backed by effective support systems. In contrast, lung cancer, while currently classified as emerging, is rapidly evolving thanks to advancements in immunotherapy and targeted treatments. The increasing prevalence of lung cancer has prompted the healthcare system to adapt and innovate, making this segment a critical focus for future market growth. As awareness of supportive care benefits rises, both segments are expected to play crucial roles in the market.
By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Providers (Fastest-Growing)
In the South Korea cancer supportive-care market, Hospital Pharmacies hold the largest market share, serving as primary dispensers for patients requiring supportive care during cancer treatment. Drug Stores and Retail Pharmacies also contribute significantly to the distribution landscape, while Online Providers are gaining traction. The rising demand for online services reflects changing consumer preferences, particularly increased convenience and accessibility for patients seeking medications and support. Growth trends in this segment are driven by the expansion of online platforms that provide patients with easier access to medications. Moreover, the increasing incidence of cancer in South Korea fuels demand across all channels, with Hospital Pharmacies continuing to dominate the market. Enhanced services and enhanced patient care options are also vital drivers, as they cater to the need for personalized and efficient treatment solutions.
Hospital Pharmacies (Dominant) vs. Online Providers (Emerging)
Hospital Pharmacies exemplify the dominant force in the South Korea cancer supportive-care market. They offer a wide range of medications and personalized services tailored to the specific needs of cancer patients, leveraging their direct association with healthcare facilities. Conversely, Online Providers represent an emerging segment, rapidly reshaping distribution dynamics through technology. They provide convenience and broad access, appealing to tech-savvy patients who prefer the ease of ordering medications online. While Hospital Pharmacies maintain strong patient relationships through professional consultation, Online Providers are gaining momentum by offering competitive pricing and delivery options, thus positioning themselves as vital players in an evolving market.
Key Players and Competitive Insights
The cancer supportive-care market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for innovative therapies and supportive treatments. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Amgen (US) are actively shaping the market through strategic initiatives focused on innovation and partnerships. Roche (CH) emphasizes its commitment to personalized medicine, leveraging advanced diagnostics to enhance treatment outcomes. Meanwhile, Bristol-Myers Squibb (US) is concentrating on expanding its immunotherapy portfolio, which is pivotal in addressing the growing need for effective cancer treatments. Amgen (US) appears to be focusing on enhancing patient access to its therapies, indicating a trend towards patient-centric approaches that could redefine competitive dynamics.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse strategies, yet the collective influence of major companies like Roche (CH) and Bristol-Myers Squibb (US) is significant, as they set benchmarks for innovation and operational excellence.
In October Roche (CH) announced a strategic partnership with a local biotech firm to co-develop a novel supportive care therapy aimed at alleviating chemotherapy-induced side effects. This collaboration not only enhances Roche's product pipeline but also underscores the importance of local partnerships in addressing specific patient needs in South Korea. Such initiatives may strengthen Roche's market position by aligning its offerings with local healthcare demands.
In September Bristol-Myers Squibb (US) launched a new patient support program designed to provide comprehensive resources for patients undergoing cancer treatment. This initiative reflects a broader trend towards holistic patient care, which is becoming increasingly vital in the competitive landscape. By investing in patient support, Bristol-Myers Squibb (US) is likely to enhance brand loyalty and improve treatment adherence, which could translate into better clinical outcomes.
In August Amgen (US) expanded its distribution network in South Korea, aiming to improve access to its supportive care products. This strategic move is indicative of a growing emphasis on supply chain reliability and patient access, which are critical in a market where timely treatment can significantly impact patient outcomes. Amgen's efforts to streamline distribution may position it favorably against competitors who are still navigating logistical challenges.
As of November current trends in the cancer supportive-care market include a pronounced shift towards digitalization and the integration of artificial intelligence in treatment protocols. Companies are increasingly forming strategic alliances to leverage technological advancements, which is reshaping the competitive landscape. The focus appears to be shifting from price-based competition to innovation and supply chain reliability, suggesting that future differentiation will hinge on the ability to deliver cutting-edge solutions that enhance patient care and operational efficiency.
Key Companies in the South Korea Cancer Supportive Care Market include
Industry Developments
Recent developments in the South Korea Cancer Supportive Care Market have been notable, particularly with advancements in therapeutics and supportive treatments. Companies like Genexine and PharmAbcine are focusing on innovative oncology solutions that enhance patient quality of life during treatment. In recent months, Eone Diagnomics Genome Center has made strides in genomic research, potentially improving personalized medicine approaches in cancer care. In a significant merger in August 2023, Hanmi Pharmaceutical announced its acquisition of a biotech firm specializing in immunotherapy, which strengthens its position in the market.
Moving toward growth, Celltrion and LG Chem have reported considerable expansions in their product lines, reflecting a rise in market valuation that is positively impacting their operational capacity and investor confidence. Furthermore, the Korean government has committed to increasing funding for cancer research initiatives, demonstrating its commitment to advancing cancer care. The market has been influenced by ongoing innovations and investments from key players such as Samsung Biologics and SK Biopharmaceuticals, aiming to establish South Korea as a pivotal hub for cancer supportive therapies in the Asia-Pacific region.
Future Outlook
South Korea Cancer Supportive Care Market Future Outlook
The Cancer Supportive Care Market is projected to grow at 2.5% CAGR from 2025 to 2035, driven by increasing patient needs and advancements in treatment options.
New opportunities lie in:
- Development of telehealth platforms for remote patient monitoring
- Integration of AI-driven analytics for personalized care plans
- Expansion of home-based palliative care services to enhance accessibility
By 2035, the market is expected to achieve substantial growth, reflecting evolving patient care dynamics.
Market Segmentation
South Korea Cancer Supportive Care Market Type Outlook
- ESA (Erythropoiesis-Stimulating Agents)
- G-CSFs (Granulocyte Colony-Stimulating Factors)
- Antiemetics
- Bisphosphonates
- Opioids
- NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
- Others
South Korea Cancer Supportive Care Market Application Outlook
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Stomach Cancer
- Others
South Korea Cancer Supportive Care Market Distribution Channel Outlook
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
Report Scope
| MARKET SIZE 2024 | 522.75(USD Million) |
| MARKET SIZE 2025 | 535.82(USD Million) |
| MARKET SIZE 2035 | 686.05(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Bristol-Myers Squibb (US), Amgen (US), Merck & Co (US), Novartis (CH), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB) |
| Segments Covered | Type, Application, Distribution Channel |
| Key Market Opportunities | Integration of telehealth solutions enhances patient access in the cancer supportive-care market. |
| Key Market Dynamics | Rising demand for personalized therapies drives innovation in the cancer supportive-care market in South Korea. |
| Countries Covered | South Korea |
FAQs
What was the overall market valuation of the cancer supportive-care market in 2024?
The overall market valuation was $522.75 Million in 2024.
What is the projected market valuation for the cancer supportive-care market in 2035?
The projected valuation for 2035 is $686.05 Million.
What is the expected CAGR for the cancer supportive-care market during the forecast period 2025 - 2035?
The expected CAGR for the market during the forecast period is 2.5%.
Which companies are considered key players in the cancer supportive-care market?
Key players include Roche, Bristol-Myers Squibb, Amgen, Merck & Co, Novartis, Pfizer, Eli Lilly and Company, and AstraZeneca.
What are the revenue ranges for Erythropoiesis-Stimulating Agents in the market?
The revenue range for Erythropoiesis-Stimulating Agents is $50.0 Million to $65.0 Million.
How much revenue is projected for Antiemetics in the cancer supportive-care market?
Antiemetics are projected to generate revenue between $100.0 Million and $130.0 Million.
What is the revenue range for Hospital Pharmacies as a distribution channel?
Hospital Pharmacies are expected to generate revenue between $200.0 Million and $260.0 Million.
What is the revenue range for Online Providers in the distribution of cancer supportive-care products?
Online Providers are projected to generate revenue between $172.75 Million and $236.05 Million.
Which cancer type is expected to generate the highest revenue in the market?
Breast Cancer is expected to generate the highest revenue, ranging from $78.43 Million to $101.23 Million.
What is the revenue range for Opioids in the cancer supportive-care market?
Opioids are projected to generate revenue between $80.0 Million and $100.0 Million.
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”